I Have Had Hsv1 for Years, Does That Mean My Baby Has Immunities

J Zhejiang Univ Sci B. 2017 Apr; 18(four): 277–288.

Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection^*

Received 2016 Oct 13; Accepted 2017 Jan 7.

Abstract

Herpes simplex virus blazon one (HSV-1), a neurotropic member of the alphaherpes virus family, is among the most prevalent and successful homo pathogens. HSV-1 can cause serious diseases at every stage of life including fatal disseminated disease in newborns, cold sores, center illness, and fatal encephalitis in adults. HSV-1 infection can trigger rapid immune responses, and efficient inhibition and clearance of HSV-1 infection rely on both the innate and adaptive immune responses of the host. Multiple strategies take been used to restrict host innate immune responses by HSV-1 to facilitate its infection in host cells. The adaptive immunity of the host plays an important role in inhibiting HSV-1 infections. The activation and regulation of T cells are the important aspects of the adaptive immunity. They play a crucial role in host-mediated amnesty and are important for immigration HSV-one. In this review, nosotros examine the findings on T cell immune responses during HSV-i infection, which hold promise in the design of new vaccine candidates for HSV-1.

Keywords: Canker simplex virus type 1, Adaptive amnesty, T cells, Vaccine

1. Introduction

Herpes simplex virus type 1 (HSV-1), from the alphaherpes virus subfamily, is an enveloped, nuclear-replicating, and large double-stranded DNA virus. The genome of HSV-one is an well-nigh 152 kb linear double-stranded GC-rich DNA sequence, and contains two unique regions called the long unique region (U_L) and the short unique region (U_S) (Fig. ​ 1a), which encodes at to the lowest degree 84 proteins (Kieff et al., 1971). The genome of HSV-1 is located within the nucleocapsid, which is surrounded by a group of tegument proteins. The nucleocapsid and tegument proteins are surrounded by a lipid envelope studded with glycoproteins which are of import for bounden to and entry into new susceptible cells (Egan et al., 2013). The major steps of the life cycle of HSV-one are: entry into the host jail cell, viral cistron expression, genome replication, virion assembly, and release of new infectious virus (Fig. ​ 1b) (Kukhanova et al., 2014). Three classes of genes of HSV-1 are expressed in a consecutive style, including immediate early on (IE) genes, early genes, and belatedly genes. The products of IE genes regulate the expressions of early genes and late genes (Harkness et al., 2014).

Genome data and life bike of HSV-1

(a) Structure of the HSV-i DNA. The unique long (U₅₀) region is flanked past the terminal repeat (TR_L) and the internal repeat (IR₅₀). The unique short (U_Southward) region is bounded by the terminal repeat (TR_S) and the internal repeat (IR_S). (b) HSV-1 life cycle. ane: entry into the host cell; 2: viral factor expression; 3: genome replication; 4: virion assembly; 5: release of new infectious virus

The principal infection of HSV-1 is mainly in epithelial or mucosal cells, and and so establishes a latent infection when information technology is transported to the sensory ganglia (Nicoll et al., 2012). During HSV-1 latent infection, the genome transcription is inhibited with the exception of a sequence encoding the latency-associated transcripts (LATs) (Wagner and Bloom, 1997; Preston, 2000; Efstathiou and Preston, 2005). The renewed lytic infection at epithelial or mucosal cells happens when there is reactivation of latent HSV-1 (Wuest and Carr, 2008).

HSV-1 infection is widespread, and its seropositivity may comprehend more than than 70% of the globe population. In developing countries, HSV-ane infection is universal, and acquired from intimate contact with family in early childhood (Whitley et al., 1988). In developed countries, some data suggest that conquering of HSV-1 is delayed from early babyhood to young adulthood (Hashido et al., 1999; Mertz et al., 2003). In the United States, 65% of people have antibodies to HSV-ane, which is similar to the epidemiology in Europe (Xu et al., 2002). HSV-1 infection can cause clinical disease in various parts of the human being body, such every bit genitalia, eye, oral, and central nervous system (CNS). The diseases associated with HSV-1 are listed in Table ​ 1.

Table 1

Diseases associated with HSV-1 infection

Infected body part	Disease	Reference
Pare	Cutaneous canker	Zendri et al., 2005; Faron et al., 2016
	Genital canker	Nieuwenhuis et al., 2006; Khoury-Hanold et al., 2016
Ocular	Canker simplex keratitis (HSK)	Burrel et al., 2013; Tsatsos et al., 2016
	Uveitis	Krichevskaia et al., 2005; van Velzen et al., 2013
	Acute retinal necrosis	Mora et al., 2009; Fong et al., 2014
Orolabial	Cold sores	Richardson et al., 2013; Chi et al., 2015
	Oral ulcers	Sepulveda et al., 2005; Nicolatou-Galitis et al., 2006
CNS	Encephalitis	Bradshaw and Venkatesan, 2016; Eriksson et al., 2016
	Meningitis	Eisenstein et al., 2004; Azadfar et al., 2014
	Alzheimer'south disease	Beffert et al., 1998; Itzhaki et al., 1998

Inhibition of viral infection and clearance of the virus from infected cells rely on the innate and adaptive immunity of the host. The host innate immune system has evolved soluble components and specialized cells to cake viral infection, replication, and shedding (Medzhitov and Janeway, 2000; Kawai and Akira, 2006). During viral infection, design recognition receptors (PRRs) have a role in detecting the viral pathogen-associated molecular patterns (PAMPs) in infected cells. The activated PRRs, such as Toll-like receptors (TLRs) and retinoic acid inducible gene-I (RIG-I)-similar receptors (RLRs), volition induce interferon production and cytokine release (Akira et al., 2006). The cellular PRRs to detect HSV-one PAMPs have been reviewed extensively (Paludan et al., 2011; Melchjorsen, 2012). The type I interferon (IFN) signal pathway is the important first line of defense for the host against HSV-i. The innate immune cells including monocytes, neutrophils, dendritic cells (DCs), macrophages, and natural killer (NK) cells also play a crucial role in inhibiting HSV-1 infection (Kodukula et al., 1999; Barr et al., 2007; Spud et al., 2008; Zheng et al., 2008; Mott et al., 2011; 2014; Frank et al., 2012; Kim et al., 2012; Molesworth-Kenyon et al., 2012; Swiecki et al., 2013; Vogel et al., 2014; Menasria et al., 2015). During infection, HSV-1 has developed multiple mechanisms to evade innate host immune responses and benumb host antiviral elements (Paladino and Mossman, 2009; Suazo et al., 2015; Su et al., 2016). Although the functions of host innate amnesty such as blazon I IFN and innate allowed cell activity are need to suppress HSV-ane replication and infection, the generation of both CD8⁺ and CD4⁺ T cells is ultimately required to inhibit viral infection, bulldoze HSV-1 into latency, and repress reactivation. This review will summarize and discuss current findings of the T cell immune response during HSV-1 infection, which could facilitate the attempts of more constructive vaccine development for treating HSV-1 infection.

two. Immune responses of CD8⁺ T cells during HSV-1 infection

Among the immune cells involved in the immunity induced by pathogen invasion, CD8⁺ T cells play a fundamental office in host adaptive immunity against many intracellular pathogens and clearing the viruses from the host (Wiesel et al., 2009; Kalia et al., 2010). Post-obit pathogen recognition in the context of major histocompatibility complex grade I (MHC-I) on antigen presenting cells (APCs), the naive CD8⁺ T cells could be differentiated into Tc1, Tc2, or Tc17 cells (Mosmann et al., 1997; Lee et al., 2011; Zhang and Bevan, 2011). During viral infection, the immune response of CD8⁺ T cells was divided into three characteristic phases, which are the initial activation and expansion, a wrinkle stage, and the establishment and maintenance of memory (Kaech et al., 2002a). During the acute phase of viral infection in humans, the robust immune responses of CD8⁺ T cells take also been observed (Callan et al., 1998). At the tiptop of proliferation, there is up to 10⁴-to ten⁵-fold expansion of CD8⁺ T cells, which divide approximately every vi to eight h, and then undergo activation and differentiation after this dramatic proliferation (Murali-Krishna et al., 1998). Upon antigenic stimulation, the expressions of granzymes and perforin are up-regulated past CD8⁺ T cells, and then these cells become cytolytic and gain the power to enter non-lymphoid tissues (Bachmann et al., 1999; Cerwenka et al., 1999; Kaech et al., 2002a; 2002b; Wherry et al., 2003). CD8⁺ T cells also surreptitious the IFN-γ when responding to viral infection, and IFN-γ promotes presentation of antigens to CD8⁺ T cells through enhanced processing of viral peptides for loading into MHC-I, which promotes immune response and inhibits viral infection (Groettrup et al., 1996; Schroder et al., 2004).

Previous studies indicated that CD8⁺ T cells might play a crucial role in restricting HSV-ane infection (Marrack and Kappler, 1987; Simmons, 1989). In line with the classic paradigm that HSV-one infection is controlled past CD8⁺ T cells, MHC-I-restricted CD8⁺ T cells can be recovered from lymph nodes draining into herpetic lesions after HSV-1 infection on 24-hour interval 4 (Nash et al., 1980). CD8⁺ T cells also have an ability to shut down HSV-1 infection in the trigeminal ganglia (TG) and prevent neurologic damage, and the response of CD8⁺ T cells could exist divided into acute and latent phases (Simmons and Tscharke, 1992; Liu et al., 2000). In the mouse model, the infiltration peaks of CD8⁺ T cells in mouse ganglia occurred on Mean solar day 12, and a great number of CD8⁺ T cells persisted in the ganglia for up to 90 d. Using a murine flank scarification model, CD8⁺ T cells were observed to be involved in inhibiting HSV-i replication in the draining ganglia (Simmons et al., 1992). In terms of effector molecules that are associated with CD8⁺ T cells mediating immunity, alternatively it was reported that IFN-γ non simply might exert an antiviral event and block the replication of numerous viruses in vitro, but also has an antiviral activity in controlling HSV-1 infection in main human neurons and astrocytes (Li et al., 2011; 2012). Furthermore, another possible effector molecule is granzyme A (GrA), and the animals deficient in GrA show the decreased viral clearance from infection sites after peripheral HSV-ane inoculation (Pereira et al., 2001).

The CD8⁺ T cells might interact with many APCs during HSV-one infection, such as DCs and ganglionic cells. The type and condition of APC used to characterize CD8⁺ T jail cell responses are as well critically important for the inhibition of HSV-1 infection. Compared with B cells, the fibroblasts are more than susceptible to HSV-one-mediated downwards-regulation of human leukocyte antigen class I (HLA-I) and they were observed to poorly re-stimulate retentiveness CD8⁺ T prison cell responses (Yasukawa and Zarling, 1984; Kohl, 1991; Tigges et al., 1996).

Tissue-resident retentivity T cells (T_RM cells) are a subtype of retentivity lymphocytes and reside in nonlymphoid tissues in humans and mice (Schenkel and Masopust, 2014). CD8⁺ T_RM cells, a novel grade of CD8⁺ retentiveness T cells, have been well characterized (Krzysiek et al., 2013). During HSV-1 infection, virus-specific CD8⁺ T_RM cells are created in both ganglia and mucosa (Khanna et al., 2003; Gebhardt et al., 2009; Ariotti et al., 2014). CD8⁺ T_RM cells exist in non-lymphoid tissue compartments for long periods, and now these cells are besides found in brain, kidney, joints, and other non-barrier tissues, which can trigger protective innate and adaptive immunity (Schenkel et al., 2014). CD8⁺ T_RM cells could express the effector molecules IFN-γ and granzyme B (GrB), and more than these cells are not replenished from the circulating CD8⁺ T jail cell pool (Mackay et al., 2012). The roles of CD8⁺ T_RM cells are listed in Fig. ​ 2.

Role of CD8⁺ T_RM cells

3. Allowed response of CD4⁺ T cells during HSV-1 infection

In the host adaptive allowed system, CD4⁺ T cells are another important co-operative, which not merely accept the ability to regulate an effective immune response to pathogens, but as well have a role in control of host survival. Naive CD4⁺ T cells could differentiate into Th1, Th2, Th17, and induced regulatory T (iTreg) cells through interaction with antigen-MHC circuitous, and CD4⁺ T cell differentiation depends on the cytokines of the microenvironment (Luckheeram et al., 2012; Zheng, 2013). CD4⁺ T cells have power to restrict and eliminate acute viral infection, and depend on the distinct phenotypes with their respective cytokine profiles. CD4⁺ T cells too modulate the functions of adaptive immunity and the innate immune cells (Sant and McMichael, 2012). Th1 cells have been regarded every bit critical for immunity to intracellular microorganisms and Th2 cells for immunity to many extracellular pathogens, including helminthes (Mosmann and Coffman, 1989; Paul and Seder, 1994). Treg cells function is needed to limit the extent of virus-induced inflammatory lesions, which implies that expanding and activating Tregs could be therapeutically valuable (Sehrawat and Rouse, 2011). During HSV-1 infection, the expression of IL-17 was up-regulated mainly through the Th17 cells in host cornea. Th1 cells are also responsible for orchestrating herpes stromal keratitis (HSK) during viral infection (Suryawanshi et al., 2011).

In the HSV-i corneal infection model, HSV-1 replication is largely eliminated past four–half dozen solar day post infection (dpi), and the CD4⁺ T cells that mediate HSK infiltrate the cornea around 7 dpi (Lepisto et al., 2006; Yun et al., 2014). Previous report has shown that the CD4⁺ T cells are important for preventing genital affliction in a mice model during HSV-i infection (Kuklin et al., 1998). When the mice are inoculated intravaginally (i.vag.) with HSV-1, CD4⁺ T cells can accumulate and persist within the spinal cords and dorsal root ganglia, which suggested that CD4⁺ T cells have the ability to clear virus from both neural and genital sites afterwards HSV-one chief infection (Johnson et al., 2008). It had been demonstrated that the CD4⁺CD25⁺ Tregs participate in T cell immune response to HSV-1 (Suvas et al., 2003). Following i.vag. inoculation of HSV-1, the number of CD4⁺ T cells from iliac lymph nodes, spinal cords, or dorsal root ganglia more often than not peaked around 6 or viii dpi, and these cells increased expression of the activation mark CD25, CD44, or CD69 (Johnson et al., 2008). CD4⁺ T cells are expanded in the draining lymph nodes (DLNs) and re-stimulated in the infected cornea to regulate the destructive inflammatory disease after HSV-i corneal infection (Buela and Hendricks, 2015). Recruitment of memory CD4⁺ T cells after infection of HSV-1 is besides involved in the development of Th1 cells (Sin et al., 2000). DCs are resident in the DLNs and account for the expanding of naive HSV-specific CD4⁺ T cells in DLNs and the re-stimulating of the CD4⁺ T effector cells that infiltrate the cornea to mediate HSK (Hendricks et al., 1992). CD4⁺ T cells contribute to protection against HSV-1 in mice and ablation of CD4⁺ T cells increased susceptibility in naive animals (Manickan et al., 1995a; 1995b). In the mice model, CD4⁺ T cells are sufficient and have a ability to inhibit and clear HSV-i from both neural and genital sites afterward primary infection (Johnson et al., 2008).

4. Infiltration of CD8⁺ and CD4⁺ T cells into central nervous arrangement during HSV-ane infection

Despite the fact that the CNS of a host by and large has the restrictive nature of the claret-brain bulwark (BBB), CD8⁺ and CD4⁺ T cells can infiltrate into CNS during a variety of disease states and viral infection (Stohlman et al., 1998; Marten et al., 2003). When animals are exposed to glucocorticoids, the CNSs of them are shown to be vulnerable, which could enhance the susceptibility to viral infection. In the mouse model, psychological stress tin can induce the product of glucocorticoid, which enhances the infection of HSV-1 in mice and causes the development of HSV-1 encephalitis (HSE) (Nair et al., 2007). In a mouse model of HSE, the HSV-1-specific T cells infiltrated into CNS, and the brain of the mouse had an increase in CD8⁺ and CD4⁺ T cells during HSV-i infection (Anglen et al., 2003). Multifocal brain demyelination (MBD) has been reported in susceptible mouse strains upon lip inoculation with HSV-1 and immunosuppression prevents the evolution of such lesions (Kastrukoff et al., 1987; 1993). CD8⁺ T cells appear to be involved in the focal lesions of the brain and the depletion of such cells prevents lesion development (Hudson and Streilein, 1994). Due to the limited evidence, it notwithstanding remains unclear whether CD8⁺ T cells are responsible for limitation of HSV-1 replication and spreading inside the CNS prior to an infection, or the delayed entrance of CD8⁺ T cells could result in pathology (Anglen et al., 2003).

The microglia, mstrocytes, perivascular macrophages, DCs, and endothelial cells of the brain have a role in presenting antigen to T cells in CNS (Aloisi, 1999; 2001; Aloisi et al., 2000). During HSV-1 infection, the dendritic-like cells and macrophage-like cells increase the expression of H-2K^b, which indicates a potential role of these cells to prime of HSV-1-specific CD8⁺ T cells in host CNS (Nair et al., 2007).

5. Exhaustion of CD8⁺ T cells during HSV-1 infection

The CD8⁺ T cells can be exhausted during chronic viral infection. These exhausted CD8⁺ T cells exhibit lost memory potential and poor effector function (Zajac et al., 1998; Wherry, 2011; Schietinger and Greenberg, 2014). The first report on CD8⁺ T cells exhaustion was found in mice when infected with lymphocytic choriomeningitis virus (LCMV), and virus-specific CD8⁺ T cells become less functional, every bit the infection persists, and may gradually lose their effector function, including proliferation, cytotoxicity, and cytokine production (Zajac et al., 1998). In addition, the exhaustion of CD8⁺ T prison cell function has been demonstrated in several man chronic virus infections, including hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The inhibitory receptors are expressed in exhausted CD8⁺ T cells, such equally programmed cell death protein 1 (PD-one), T-cell immunoglobulin domain and mucin domain-iii (Tim-3), cluster of differentiation 244 (CD244), B-and T-lymphocyte attenuator (BTLA), cytotoxic T-lymphocyte associated protein 4 (CTLA-four), CD160, and killer cell lectin-similar receptor subfamily Thou member 1 (KLRG1) (Bengsch et al., 2010; Wherry, 2011).

HSV-1 can reactivate from the TG, where at that place is a sizable pool of virus-specific CD8⁺ T cells. This phenomenon may depend on exhausting CD8⁺ T cells (Hoshino et al., 2007; Chentoufi et al., 2010). PD-i is the well-nigh common inhibitory mark expressed in wearied CD8⁺ T cells (Hairdresser et al., 2006; Petrovas et al., 2007; Fourcade et al., 2010; Sakuishi et al., 2010). Besides the expression of PD-1, the loftier expressions of Tim-iii and CTLA-4 were as well detected on the HSV-1-specific CD8⁺ T cells from LAT⁺ TG, which helped to discriminate betwixt burnout and activation (Srivastava et al., 2016). During HSV-1 latency infection, LAT influences the CD8⁺ T cell levels and exhaustion. LAT⁺ HSV-one can nowadays more than viral agent to CD8⁺ T cells, and this leads to increment in the expression of PD-1/Tim-3 and CD8⁺ T cell burnout. There are 3 subsets of exhausted CD8⁺ T cells in the TG of mice latently infected past HSV-i, the first 1 expressing PD-ane, the 2d expressing Tim-3, and the third expressing both PD-1 and Tim-3 (Allen et al., 2011). The GrB of CD8⁺ T cells plays a major role in cytotoxic lytic granule-mediated apoptosis of cells. HSV-one LAT non only restricts the GrB-induced cell apoptosis, just too inhibits the GrB-induced cleavage of caspase-3 (Jiang et al., 2011).

6. Vaccine for HSV-ane

HSV-1 has the power to build a chief and latent infection in human being bodies, and causes serious diseases in human beings (Laing et al., 2012). It will do good public health worldwide past reducing HSV-1 infection in human beings, and the efficient and effective pathway to control viral infectious disease is to inject vaccines. However, many of people are infected by HSV-1 during childhood, and the almost of infected persons never undergo recurrent herpetic disease (Khanna et al., 2004). Therefore, the efficient and effective approach to forbid the infection of HSV-1 is prophylactic vaccination. The method to produce a therapeutic vaccine is targeting the viral proteins during HSV-ane latent infection, which proves more efficacious in restricting recurrent disease in homo beings.

The advantages and disadvantages of experimental vaccine formats, which are mixture of viral proteins, peptides, attenuated replication-competent viruses, and replication-defective viruses, are reviewed (Stanberry et al., 2000). Many vaccine types including condom and therapeutic containing viral Deoxyribonucleic acid, glycoproteins, or replication-lacking virus have been built in the past ten years. Present, the approaches to develop vaccines are focused on the mechanism of viral evasion of the host immune organization, and combination with the utilise of new and more specific adjuvants (Coleman and Shukla, 2013).

Researchers are interested in exploiting T cells to develop the vaccines, considering the T cells of the host have specific and long-term immunologic retentivity and the ability to clear the virus in vitro and in animals (Laing et al., 2012). It is known that T cells have taken part in protective immunity after vaccination and correlate with viral reactivation in creature manipulation (Noisakran and Carr, 1999; Liu et al., 2000; Sheridan et al., 2009). Some studies suggest that T cell epitope specificities vary with dissimilar clinical presentations of HSV-1, and the epitope discovery has facilitated investigation of HSV-1-specific T cells in the search for a natural allowed response (Chentoufi et al., 2008). T cells respond to a complex and serious pathogen with HSV-1, which has been decoded with a linked set up of cellular and molecular tools to reveal novel candidate vaccine antigens (Jing et al., 2012). During HSV-1 cornea infection in mouse models, it has been shown that the CD8⁺ T cells might have no influence on the immunopathology in HSV-ane. However, CD8⁺ T cells are protective at peripheral sites of infection and in the TG of the host, so a vaccine targeting CD8⁺ T cells might be particularly efficient and effective (Khanna et al., 2004).

Based on the protective immune response of T cells, information technology is important to develop a vaccine that elevates T cells. The best protection of the host during viral infection is to induce stronger cell-mediated immunity besides as better humoral responses, because viruses have used clever immune evasion strategies to inhibit the neutralizing antibody response (Coleman and Shukla, 2013). Nowadays, in that location has no specific vaccine or immunization strategy for HSV-1, but fascinating contempo work comparing HSV-1-seropositive persons with and without histories of symptomatic orolabial herpes raises the possibility that humoral response patterns to specific proteins, or T-cell response patterns to defined epitopes within HSV-ane glycoproteins, may correlate with clinical severity, offering a set of criteria for rational down-selection of vaccine candidates (Chentoufi et al., 2008; Dasgupta et al., 2012).

vii. Conclusions

In summary, HSV-ane is i of the persistent pathogens of human being beings, and can crusade a multifariousness of diseases, such as common cold sores, cutaneous herpes, genital canker, and encephalitis. HSV-1 can establish a latent infection in TG of host, while CD4⁺ and CD8⁺ T cells can control the reactivation of the HSV-1 past surrounding latently infected neurons. The interactions between the host amnesty and HSV-1 are very complicated. There is a battle between the host and HSV-ane, and construction of a potent HSV-ane-specific T cell immunity relies on multifaceted DCs priming of T cells as well as both CD4⁺ and CD8⁺ T cell cooperation at several stages and anatomic sites. Thus, favored vaccines arm-twist complex T jail cell responses, and likely also B cell responses, to generate long-lasting virus-neutralizing antibodies. Now the approaches to design the new vaccine against HSV-1 are by alluring and retaining T_RM cells in peripheral tissue locations. In any case, development of a useful HSV-one vaccine needs to overcome the challenges posed by HSV-1 to traditional vaccine strategies.

Footnotes

^*Projection supported by the Wuhan Institute of Virology (WIV) "One-Three-Five" Strategic Programs, China

Compliance with ethics guidelines: Jie ZHANG, Huan LIU, and Bin WEI declare that they accept no conflict of involvement.

This commodity does non contain any studies with human or creature subjects performed by any of the authors.

References

2. Allen SJ, Hamrah P, Gate D, et al. The role of LAT in increased CD8⁺ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol. 2011;85(nine):4184–4197. (Available from: http://dx.doi.org/10.1128/JVI.02290-10) [PMC free article] [PubMed] [Google Scholar]

3. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. In: Matsas R, Tsacopoulos Thou, editors. The Functional Roles of Glial Cells in Health and Disease. New York: Springer Science+Business organization Media; 1999. pp. 123–133. (Available from: http://dx.doi.org/x.1007/978-i-4615-4685-6_10) [Google Scholar]

6. Anglen CS, Truckenmiller ME, Schell TD, et al. The dual role of CD8⁺ T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunol. 2003;140(1-2):xiii–27. (Bachelor from: http://dx.doi.org/10.1016/S0165-5728(03)00159-0) [PubMed] [Google Scholar]

7. Ariotti S, Hogenbirk MA, Dijkgraaf FE, et al. T jail cell retention. Skin-resident retention CD8⁺ T cells trigger a country of tissue-wide pathogen alert. Scientific discipline. 2014;346(6205):101–105. (Available from: http://dx.doi.org/10.1126/science.1254803) [PubMed] [Google Scholar]

10. Barber DL, Wherry EJ, Masopust D, et al. Restoring office in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–687. (Available from: http://dx.doi.org/10.1038/nature04444) [PubMed] [Google Scholar]

16. Burrel S, Boutolleau D, Azar G, et al. Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-i isolates from immunocompetent patients with recurrent herpetic keratitis. J Clin Virol. 2013;58(1):321–324. (Bachelor from: http://dx.doi.org/10.1016/j.jcv.2013.05.001) [PubMed] [Google Scholar]

xviii. Cerwenka A, Morgan TM, Dutton RW. Naive, effector, and retentivity CD8 T cells in protection against pulmonary flu virus infection: homing properties rather than initial frequencies are crucial. J Immunol. 1999;163(10):5535–5543. [PubMed] [Google Scholar]

20. Chentoufi AA, Dasgupta G, Christensen ND, et al. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8⁺ T cell epitope-based vaccines against ocular herpes. J Immunol. 2010;184(5):2561–2571. (Available from: http://dx.doi.org/ten.4049/jimmunol.0902322) [PMC free commodity] [PubMed] [Google Scholar]

23. Dasgupta G, Chentoufi AA, Kalantari Thousand, et al. Immunodominant "asymptomatic" herpes simplex virus 1 and two protein antigens identified past probing whole-orfome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol. 2012;86(8):4358–4369. (Bachelor from: http://dx.doi.org/10.1128/JVI.07107-11) [PMC gratuitous article] [PubMed] [Google Scholar]

27. Eriksson CE, Studahl M, Bergstrom T. Acute and prolonged complement activation in the central nervous organization during herpes simplex encephalitis. J Neuroimmunol. 2016;295-296:130–138. (Available from: http://dx.doi.org/10.1016/j.jneuroim.2016.04.013) [PubMed] [Google Scholar]

28. Faron ML, Ledeboer NA, Patel A, et al. Multicenter evaluation of meridian bioscience HSV i&2 molecular assay for detection of herpes simplex virus ane and ii from clinical cutaneous and mucocutaneous specimens. J Clin Microbiol. 2016;54(8):2008–2013. (Available from: http://dx.doi.org/10.1128/JCM.00483-16) [PMC free article] [PubMed] [Google Scholar]

29. Fong CY, Aye AM, Peyman M, et al. Neonatal canker simplex virus type-i fundamental nervous arrangement disease with acute retinal necrosis. Pediatr Infect Dis J. 2014;33(4):424–426. (Available from: http://dx.doi.org/10.1097/INF.0000000000000137) [PubMed] [Google Scholar]

30. Fourcade J, Sunday Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8⁺ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–2186. (Available from: http://dx.doi.org/10.1084/jem.20100637) [PMC gratis commodity] [PubMed] [Google Scholar]

32. Gebhardt T, Wakim LM, Eidsmo Fifty, et al. Retentiveness T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524–530. (Available from: http://dx.doi.org/10.1038/ni.1718) [PubMed] [Google Scholar]

34. Harkness JM, Kader M, Deluca NA. Transcription of the herpes simplex virus 1 genome during productive and quiescent infection of neuronal and nonneuronal cells. J Virol. 2014;88(12):6847–6861. (Available from: http://dx.doi.org/10.1128/JVI.00516-14) [PMC free article] [PubMed] [Google Scholar]

35. Hashido M, Kawana T, Matsunaga Y, et al. Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. Microbiol Immunol. 1999;43(2):177–180. (Available from: http://dx.doi.org/x.1111/j.1348-0421.1999.tb02390.x) [PubMed] [Google Scholar]

36. Hendricks RL, Janowicz Yard, Tumpey TM. Critical role of corneal langerhans cells in the CD4-but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas. J Immunol. 1992;148(8):2522–2529. [PubMed] [Google Scholar]

37. Hoshino Y, Pesnicak L, Cohen JI, et al. Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate straight with viral load and inversely with number of infiltrating CD8⁺ T cells. J Virol. 2007;81(15):8157–8164. (Available from: http://dx.doi.org/x.1128/JVI.00474-07) [PMC free article] [PubMed] [Google Scholar]

38. Hudson SJ, Streilein JW. Functional cytotoxic T cells are associated with focal lesions in the brains of SJL mice with experimental herpes simplex encephalitis. J Immunol. 1994;152(xi):5540–5547. [PubMed] [Google Scholar]

forty. Jiang 10, Chentoufi AA, Hsiang C, et al. The herpes simplex virus blazon 1 latency-associated transcript tin can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-jail cell killing. J Virol. 2011;85(five):2325–2332. (Bachelor from: http://dx.doi.org/10.1128/JVI.01791-10) [PMC free commodity] [PubMed] [Google Scholar]

41. Jing L, Haas J, Chong TM, et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest. 2012;122(two):654–673. (Available from: http://dx.doi.org/x.1172/JCI60556) [PMC gratuitous article] [PubMed] [Google Scholar]

42. Johnson AJ, Chu CF, Milligan GN. Effector CD4⁺ T-cell interest in clearance of infectious herpes simplex virus blazon one from sensory ganglia and spinal cords. J Virol. 2008;82(19):9678–9688. (Available from: http://dx.doi.org/10.1128/JVI.01159-08) [PMC free article] [PubMed] [Google Scholar]

43. Kaech SM, Wherry EJ, Ahmed R. Effector and retention T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;ii(4):251–262. (Bachelor from: http://dx.doi.org/10.1038/nri778) [PubMed] [Google Scholar]

45. Kalia V, Sarkar S, Ahmed R. CD8 T-cell memory differentiation during acute and chronic viral infections. In: Zanetti M, Schoenberger SP, editors. Retention T Cells. New York: Springer Scientific discipline+Business Media; 2010. pp. 79–95. (Bachelor from: http://dx.doi.org/10.1007/978-1-4419-6451-9_7) [PubMed] [Google Scholar]

46. Kastrukoff LF, Lau AS, Kim SU. Multifocal CNS demyelination following peripheral inoculation with herpes simplex virus blazon one. Ann Neurol. 1987;22(1):52–59. (Available from: http://dx.doi.org/10.1002/ana.410220113) [PubMed] [Google Scholar]

47. Kastrukoff LF, Lau As, Leung GY, et al. Contrasting furnishings of immunosuppression on canker simplex virus type I (HSV I) induced central nervous organization (CNS) demyelination in mice. J Neurol Sci. 1993;117(1-2):148–158. (Available from: http://dx.doi.org/10.1016/0022-510X(93)90167-W) [PMC gratis article] [PubMed] [Google Scholar]

52. Kieff ED, Bachenheimer SL, Roizman B. Size, composition, and structure of the deoxyribonucleic acid of herpes simplex virus subtypes i and 2. J Virol. 1971;8(ii):125–132. [PMC free article] [PubMed] [Google Scholar]

53. Kim Yard, Osborne NR, Zeng Westward, et al. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J Immunol. 2012;188(9):4158–4170. (Bachelor from: http://dx.doi.org/10.4049/jimmunol.1103450) [PubMed] [Google Scholar]

54. Kodukula P, Liu T, Rooijen NV, et al. Macrophage command of herpes simplex virus blazon 1 replication in the peripheral nervous system. J Immunol. 1999;162(5):2895–2905. [PubMed] [Google Scholar]

56. Krichevskaia GI, Andzhelov VO, Katargina LA, et al. Reactivation of persistent herpes virus infection as a factor of endogenous uveitis in children. Vestn Oftalmol. 2005;121(2):22–24. (in Russian) [PubMed] [Google Scholar]

59. Kuklin NA, Daheshia 1000, Chun S, et al. Part of mucosal amnesty in herpes simplex virus infection. J Immunol. 1998;160(12):5998–6003. [PubMed] [Google Scholar]

64. Li J, Ye L, Wang 10, et al. Consecration of interferon-λ contributes to Toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes. J Neurosci Res. 2012;90(2):399–406. (Available from: http://dx.doi.org/x.1002/jnr.22758) [PMC free article] [PubMed] [Google Scholar]

67. Mackay LK, Stock AT, Ma JZ, et al. Long-lived epithelial immunity by tissue-resident retentivity T (TRM) cells in the absenteeism of persisting local antigen presentation. Proc Natl Acad Sci USA. 2012;109(18):7037–7042. (Bachelor from: http://dx.doi.org/10.1073/pnas.1202288109) [PMC free article] [PubMed] [Google Scholar]

68. Manickan E, Rouse RJ, Yu Z, et al. Genetic immunization against herpes simplex virus. Protection is mediated by CD4⁺ T lymphocytes. J Immunol. 1995;155(1):259–265. [PubMed] [Google Scholar]

69. Manickan East, Francotte M, Kuklin N, et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity confronting herpes simplex virus through CD4⁺ Th1⁺ T cells. J Virol. 1995;69(8):4711–4716. [PMC free article] [PubMed] [Google Scholar]

76. Molesworth-Kenyon SJ, Popham Due north, Milam A, et al. Resident corneal cells communicate with neutrophils leading to the production of IP-10 during the master inflammatory response to HSV-ane infection. Int J Inflam. 2012;2012:810359. (Bachelor from: http://dx.doi.org/10.1155/2012/810359) [PMC costless article] [PubMed] [Google Scholar]

80. Mott KR, Gate D, Zandian Thou, et al. Macrophage IL-12p70 signaling prevents HSV-ane-induced CNS autoimmunity triggered by autoaggressive CD4⁺ Tregs. Invest Ophthalmol Vis Sci. 2011;52(five):2321–2333. (Available from: http://dx.doi.org/10.1167/iovs.10-6536) [PMC free commodity] [PubMed] [Google Scholar]

82. Murali-Krishna Thou, Altman JD, Suresh Chiliad, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998;8(2):177–187. (Available from: http://dx.doi.org/10.1016/S1074-7613(00)80470-seven) [PubMed] [Google Scholar]

83. Murphy EA, Davis JM, Brown Every bit, et al. Effect of IL-6 deficiency on susceptibility to HSV-ane respiratory infection and intrinsic macrophage antiviral resistance. J Interferon Cytokine Res. 2008;28(10):589–595. (Available from: http://dx.doi.org/ten.1089/jir.2007.0103) [PubMed] [Google Scholar]

84. Nair A, Hunzeker J, Bonneau RH. Modulation of microglia and CD8⁺ T cell activation during the development of stress-induced herpes simplex virus type-one encephalitis. Brain Behav Immun. 2007;21(6):791–806. (Available from: http://dx.doi.org/10.1016/j.bbi.2007.01.005) [PubMed] [Google Scholar]

85. Nash AA, Quartey-Papafio R, Wildy P. Cell-mediated amnesty in canker simplex virus-infected mice: functional analysis of lymph node cells during periods of acute and latent infection, with reference to cytotoxic and retentiveness cells. J Gen Virol. 1980;49(two):309–317. (Available from: http://dx.doi.org/10.1099/0022-1317-49-2-309) [PubMed] [Google Scholar]

86. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer. 2006;xiv(seven):753–762. (Available from: http://dx.doi.org/10.1007/s00520-005-0006-five) [PubMed] [Google Scholar]

88. Nieuwenhuis RF, van Doornum GJ, Mulder PG, et al. Importance of herpes simplex virus type-1 (HSV-1) in primary genital herpes. Acta Derm Venereol. 2006;86(2):129–134. (Available from: http://dx.doi.org/10.2340/00015555-0029) [PubMed] [Google Scholar]

90. Paladino P, Mossman KL. Mechanisms employed by canker simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res. 2009;29(9):599–607. (Bachelor from: http://dx.doi.org/10.1089/jir.2009.0074) [PubMed] [Google Scholar]

93. Pereira RA, Scalzo A, Simmons A. Cutting border: a NK complex-linked locus governs acute versus latent herpes simplex virus infection of neurons. J Immunol. 2001;166(ten):5869–5873. (Bachelor from: http://dx.doi.org/10.4049/jimmunol.166.ten.5869) [PubMed] [Google Scholar]

94. Petrovas C, Toll DA, Mattapallil J, et al. SIV-specific CD8⁺ T cells express high levels of PD1 and cytokines merely take impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood. 2007;110(iii):928–936. (Available from: http://dx.doi.org/10.1182/blood-2007-01-069112) [PMC gratis article] [PubMed] [Google Scholar]

104. Sepulveda Eastward, Brethauer U, Rojas J, et al. Oral ulcers in children under chemotherapy: clinical characteristics and their relation with herpes simplex virus blazon 1 and Candida albicans . Med Oral Patol Oral Cir Bucal. 2005;x(Suppl. one):E1–E8. [PubMed] [Google Scholar]

105. Sheridan BS, Cherpes TL, Urban J, et al. Reevaluating the CD8 T-jail cell response to herpes simplex virus type 1: interest of CD8 T cells reactive to subdominant epitopes. J Virol. 2009;83(5):2237–2245. (Bachelor from: http://dx.doi.org/ten.1128/JVI.01699-08) [PMC free article] [PubMed] [Google Scholar]

108. Simmons A, Tscharke D, Speck P. The role of immune mechanisms in command of herpes simplex virus infection of the peripheral nervous system. Curr Tiptop Microbiol Immunol. 1992;179:31–56. [PubMed] [Google Scholar]

109. Sin J, Kim JJ, Pachuk C, et al. DNA vaccines encoding interleukin-8 and rantes enhance antigen-specific Th1-type CD4⁺ T-prison cell-mediated protective amnesty against herpes simplex virus type 2 in vivo. J Virol. 2000;74(23):11173–11180. (Available from: http://dx.doi.org/10.1128/JVI.74.23.11173-11180.2000) [PMC gratis article] [PubMed] [Google Scholar]

110. Srivastava R, Dervillez 10, Khan AA, et al. The herpes simplex virus latency-associated transcript factor is associated with a broader repertoire of virus-specific wearied CD8⁺ T cells retained within the trigeminal ganglia of latently infected HLA transgenic rabbits. J Virol. 2016;90(8):3913–3928. (Available from: http://dx.doi.org/10.1128/JVI.02450-fifteen) [PMC costless commodity] [PubMed] [Google Scholar]

111. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of canker simplex virus disease through immunization. Clin Infect Dis. 2000;30(three):549–566. (Available from: http://dx.doi.org/10.1086/313687) [PubMed] [Google Scholar]

112. Stohlman SA, Bergmann CC, Lin MT, et al. CTL effector function within the key nervous organisation requires CD4⁺ T cells. J Immunol. 1998;160(6):2896–2904. [PubMed] [Google Scholar]

118. Tigges MA, Leng S, Johnson DC, et al. Human herpes simplex virus (HSV)-specific CD8⁺ CTL clones recognize HSV-2-infected fibroblasts afterwards treatment with IFN-γ or when virion host shutoff functions are disabled. J Immunol. 1996;156(10):3901–3910. [PubMed] [Google Scholar]

119. Tsatsos Thousand, MacGregor C, Athanasiadis I, et al. Canker simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Exp Ophthalmol. 2016;44(9):824–837. (Available from: http://dx.doi.org/x.1111/ceo.12785) [PubMed] [Google Scholar]

120. van Velzen M, Missotten T, van Loenen FB, et al. Acyclovir-resistant herpes simplex virus type ane in intra-ocular fluid samples of herpetic uveitis patients. J Clin Virol. 2013;57(3):215–221. (Available from: http://dx.doi.org/x.1016/j.jcv.2013.03.014) [PubMed] [Google Scholar]

121. Vogel K, Thomann Southward, Vogel B, et al. Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus blazon 1 infections. Immunology. 2014;143(4):588–600. (Available from: http://dx.doi.org/10.1111/imm.12337) [PMC free commodity] [PubMed] [Google Scholar]

122. Wagner EK, Bloom DC. Experimental investigation of herpes simplex virus latency. Clin Microbiol Rev. 1997;10(3):419–443. [PMC free article] [PubMed] [Google Scholar]

124. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective amnesty of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225–234. (Available from: http://dx.doi.org/10.1038/ni889) [PubMed] [Google Scholar]

128. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with canker simplex virus type 1 and type 2 in the united states, 1988-1994. J Infect Dis. 2002;185(8):1019–1024. (Bachelor from: http://dx.doi.org/10.1086/340041) [PubMed] [Google Scholar]

129. Yasukawa M, Zarling JM. Homo cytotoxic T cell clones directed confronting canker simplex virus-infected cells. I. Lysis restricted past HLA form II MB and DR antigens. J Immunol. 1984;133(ane):422–427. [PubMed] [Google Scholar]

134. Zheng 1000, Fields MA, Liu Y, et al. Neutrophils protect the retina of the injected eye from infection after anterior sleeping room inoculation of HSV-1 in BALB/c mice. Invest Ophthalmol Vis Sci. 2008;49(9):4018–4025. (Bachelor from: http://dx.doi.org/ten.1167/iovs.08-1914) [PMC gratuitous article] [PubMed] [Google Scholar]

135. Zheng SG. Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive Am . J Clin Exp Immunol. 2013;2(1):94–106. [PMC free article] [PubMed] [Google Scholar]

haywoodencted1995.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394093/

Share this post